logo-loader
RNS
4basebio PLC

4basebio Plc - 4basebio Launches Enzymatic ssDNA Platform

4basebio Launches Enzymatic ssDNA Platform

4basebio PLC

("4basebio" or the "Company")

–CAMBRIDGE, UK11 May2026 –4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer, more precise genetic therapies by enabling targeted gene editing, advanced cell engineering, and innovative nucleic acid-based medicines.

Built on a proprietary enzymatic manufacturing process, the platform provides biopharma with high-purity, long-form ends protected ssDNA templates, designed to overcome critical manufacturing and performance bottlenecks associated with traditional chemical synthesis in CRISPR-based gene editing, enabling large-scale, clinically viable therapeutics.

With the growth of gene editingand with a particular need for complex "knock-in" applications, the demand for longer, purer and safer DNA templates has increased exponentially. 4basebio’s ssDNA offering enables the production of constructs up to 10,000 nucleotides with protected ends, ensuring stability, reduced immunogenicity and a cleaner path to clinical manufacturing.

The technical advantages of the platform will be showcased at the upcoming in , will deliver a presentation titled on .American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, Director of Molecular Biology and Gene Editing at 4basebioAmine Bouchareb14 May at9:00 AM EDTBoston, MA."An enzymatic ssDNA platform addresses manufacturing and performance bottlenecks in non-viral CRISPR gene editing"

“The launch of our ssDNA platform marks a pivotal milestone in our mission to provide the foundational tools for genomic medicine and personalized therapies,”.said , CEO of 4basebioAmy Walker“By replacing legacy chemical synthesis with our scalable, cell-free enzymatic approach, we are empowering our partners to design therapies without the traditional constraints of length or sequence complexity. We are not just providing DNA; we are enhancing the reliability and safety profile required for life-changing therapeutics.”

“For too long, researchers have been forced to choose between the high toxicity of double-stranded DNA or the severe length limitations of chemically synthesized oligonucleotides,”. “saidAmine BoucharebOur enzymatic platform eliminates this compromise.

“At ASGCT, I look forward to presenting data that demonstrates how our long-form ssDNA constructs significantly enhance Homology Directed Repair (HDR) gene editing efficiency while maintaining superior cell viability in sensitive primary cell types. This technology is the bridge between discovery-phase editing and large-scale clinical success.”

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.

For further enquiries, please contact:

About 4basebio

4basebio (AIM: 4BB) is a -based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality.Cambridge

For more information, visit.4basebio.com

Forward-looking statements

This announcement may contain certain statements about the future outlook for 4basebio.  Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.

--         Overcomes critical manufacturing and performance bottlenecks
        associated with traditional chemical synthesis, providing faster and
        more reliable ssDNA manufacturing to aid commercial scale up
    --         4basebio team to present at ASGCT Annual Meeting 2026 inBoston,
        MA
4basebio PLC                                          +44 (0)12 2396 7943
Dr , CEO

    Cairn Financial Advisers LLP (Nominated Adviser )
                                                          +44 (0)20 7213 0880
 /  / 

    Cavendish Capital Markets Limited (Joint Broker)      +44 (0)20 7220 0500
 / 

    RBC Capital Markets (Joint Broker)                    +44 (0)20 7653 4000
 / 

    ICR Healthcare (Media and Investor Relations)         +44 (0)203 707 5700
 /Amy WalkerJo TurnerSandy JamiesonEd DownesGeoff NashNigel BirksKathryn DeeganMatthew CoakesMary-Jane ElliottJessica Hodgson



NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read